Meredith Fonesca of SpeechVive - Chapel Hill Parkinson`s Support
Download
Report
Transcript Meredith Fonesca of SpeechVive - Chapel Hill Parkinson`s Support
Little Bubbles of Noise
Meredith Fonseca, MA CCC-SLP
How SpeechVive came to be
Dr. Huber at Purdue University
began her research in 2005
She studied changes in the voice
and asked herself, “How would I
respond if my voice changed?”
Can’t we do better than this?
Traditional Speech Therapy
The
speech therapist asks the
patient to change something such
as loudness or clarity
The
speech therapist cues the
patient to make these changes
Usually
works very well during
therapy, but being clearer and
louder at home is MUCH harder
Dr. Huber first studies how to
best cue people with PD
A
visual cue was used: patients
watched a decibel meter and
were told to target a number
An
internal cue was used:
thinking about being louder
A
unique cue was used: the
Lombard effect.
The Lombard Effect is:
When
people are in noisy
environments they
automatically speak louder
When
people speak clearer
because they are in noise
When
people change their rate
when speaking in noise
Why did the Lombard effect
work best?
Because
Because
it was an external cue
the patient was simply
responding to a reflex and not
relying on training or memory.
Dr Huber asks; What if I could
create a bubble of noise?
It’s
It
It
there when you talk
stops when you stop talking
is with you outside of
therapy when you need it most
Engineers are smart
Purdue
University engineers
made Dr. Huber her very first
portable bubble of noise.
Then
they made her 40 more
which she used in a 3 year NIH
clinical trial
SpeechVive Study: Subject
Characteristics
Age: 67.67 years
Time Since Diagnosis: 8.67 years
4 of these subjects had a deep-brain
stimulator
1 of these subjects had undergone a
pallidotomy and thalamotomy
Pre-treatment speech severity: Moderate
14 participants had previous speech
therapy
Of those 14, 8 had LSVT previously
SpeechVive
•
Patients were fitted with a SpeechVive
device
• Intensity output of the SpeechVive set to
elicit an increase of 3-5 dB from
patients during conversation
•
Wore the device in communicative
contexts 2-8 hours/day, 7 days/week
• Included reading for 30 minutes per day,
5 days/week
•
SpeechViveTM intensity output was reset
every 2 weeks
SpeechVive: Results Summary
Patients and caregivers reported
improvements in communication
90% patients improved loudness by
the end of treatment
75% of patients improved in some
way (vocal intensity, rate, and
speech clarity) by the end of
treatment
SpeechVive Treatment
You must be assessed
by a trained speech
therapist
You must commit to
working with a speech
therapist for 6-8
sessions to get the full
benefit
You must be willing to
wear the device
Sample Comments about the
SpeechVive
People no longer spoke over me like I was not there
I got more respect from people because I could talk better
It was a reminder to speak louder
My wife said I pronounced words better, more clearly
My kids thought I had a good voice after using the device
Who can use SpeechVive?
People
with softer voices
People with changes in
rate
People with changes in
clarity
Who can’t use SpeechVive
People
who can only
whisper
People with 2 hearing aids
How much is it?
SpeechVive costs $2495
Payment plans of about $75/ month are
available
Insurance does not cover the cost of the
device
Insurance will likely cover the cost of
therapy
The VA will pay for it.
How do I get one?
You must be evaluated by a speech therapist to
determine if SpeechVive is the right therapy for you
Duke University Medical Center
Chapel Hill OP Rehab
Order it directly from our website
SpeechVive will send it to your speech therapist for
proper programming
Your therapist will fit you with the device during your
next appointment.
Questions?
References
1.
Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., and Del Tredici,
K. (2004). Stages in the development of Parkinson's disease-related
pathology. Cell and Tissue Research, 318(1), 121-134.
2.
Burn, D. (2000). Parkinson's disease: An overview. The
Pharmaceutical Journal, 246, 333-337.
3.
Countryman, S. and Ramig, L.O. (1993). Effects of intensive voice
therapy on voice deficits associated with bilateral thalamotomy in
Parkinson disease: A case study. Journal of Medical SpeechLanguage Pathology, 1, 233-249.
4.
Darley, F.L., Aronson, A.E., and Brown, J.R. (1969). Clusters of
deviant speech dimensions in the dysarthria. Journal of Speech and
Hearing Research, 12, 462-496.
5.
Darley, F.L., Aronson, A.E., and Brown, J.R. (1969). Differential
diagnostic patterns of dysarthria. Journal of Speech and Hearing
Research, 12, 246-269.
References
6.
7.
8.
9.
10.
Darling, M., and Huber, J.E. (2011). Changes to articulatory
kinematics in response to loudness cues in individuals with
Parkinson’s disease. Journal of Speech, Language, and Hearing
Research, 54, 1247–1259. doi: 10.1044/1092-4388(2011/10-0024)
Holmes, R.J., Oates, J.M., Phyland, D.J., and Hughes, A.J. (2000).
Voice characteristics in the progression of Parkinson's disease.
International Journal of Language & Communication Disorders,
35(3), 407-418. doi: 10.1080/136828200410654)
Kannus, P., Sievanen, H., Palvanen, M., Jarvinen, T., and Parkkari,
J. (2005). Prevention of falls and consequent injuries in elderly
people. The Lancet, 366, 1885-1893.
Logemann, J.A., Fisher, H.B., Boshes, B., and Blonsky, E.R.
(1978). Frequency and cooccurrence of vocal tract dysfunctions
in the speech of a large sample of Parkinson patients. Journal of
Speech and Hearing Disorders, 43, p. 47-57.
MacPherson, M. K., Huber, J.E., & Snow, D.P. (2011). The
intonation-syntax interface in the speech of individuals with
Parkinson's disease. Journal and of Speech, Language and Hearing
Research, 54, 19-32.
References
11.
12.
13.
14.
15.
Obeso, J.A., Rodriguez-Oroz, M.C., Goetz, C.G., Marin, C., Kordower,
J.H., Rodrigues, M., Hirsch, E.C., Farrer, M., Schapira, A.H.V., and
Halliday, G. (2010). Missing pieces in the Parkinson’s disease puzzle.
Nature Medicine, 16(6), 653-661.
Pitts, T., Bolser, D., Rosenbek, J., Troche, M., Okun, M.S., and
Sapienza, C. (2009). Impact of expiratory muscle strength training on
voluntary cough and swallow function in Parkinson disease. Chest, 135
(5), 1301-1308.
Pitts, T., Bolser, D., Rosenbek, J., Troche, M., and Sapienza, C. (2008).
Voluntary cough production and swallow dysfunction in Parkinson’s
disease. Dysphagia, 23, 297–301.
Ramig, Lorraine O., Countryman, S., O'Brien, C., Hoehn, M., &
Thompson, L. (1996). Intensive speech treatment for patients
with Parkinson's disease: Short- and long-term comparison of two
techniques. Neurology, 47, 1496-1504.
Ramig, Lorraine O., Countryman, Stefanie, Thompson, Laetitia
L., & Horii, Yoshiyuki. (1995). Comparison of two forms of
intensive speech treatment for Parkinson disease. Journal of
Speech and Hearing Research, 38, 1232-1251.
References
16.
17.
18.
19.
20.
21.
Sadagopan, N., and Huber, J.E. (2007). Effects of loudness cues on respiration in
individuals with Parkinson's disease. Movement Disorders 22, 651-659.
Sapienza, C. M. (2008). Respiratory muscle strength training applications. Current
Opinion in Otolaryngology Head and Neck Surgery, 16, 216-220.
Wood, B.H., Bilclough, J.A., Bowron, A., and Walker, R.W. (2002). Incidence and
prediction of falls in Parkinson's disease: a prospective multidisciplinary study.
Journal of Neurology, Neurosurgery, and Psychiatry, 72(6), 721-725.
Yorkston, K.M., Beukelman, D.R., Strand, E.A., and Bell, K.R. (1999). Management
of motor speech disorders in children and adults (Second ed.). Austin: Pro-Ed.
Zgaljardic, D.J., Borod, J.C., Foldi, N.S., Mattis, P.J., Gordon, M.F., Geigin, A.,
and Eidelberg, D. (2006). An examination of executive dysfunction associated with
frontostriatal circuitry in Parkinson's disease. Journal of Clinical and Experimental
Neuropsychology, 28, 1127-1144.
Zgaljardic, D.J., Borod, J.C., Foldi, N.S., and Mattis, P. (2003). A review of the
cognitive and behavioral sequelae of Parkinson's disease: Relationship to
frontostriatal circuitry. Cognitive and Behavioral Neurology, 16, 193-210.